- Home
- BATRK vs AGIO Comparison
BATRK vs AGIO Comparison
Compare BATRK & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATRK
- AGIO
- Stock Information
- Founded
- BATRK 1991
- AGIO 2007
- Country
- BATRK United States
- AGIO United States
- Employees
- BATRK N/A
- AGIO N/A
- Industry
- BATRK Broadcasting
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- BATRK Industrials
- AGIO Health Care
- Exchange
- BATRK Nasdaq
- AGIO Nasdaq
- Market Cap
- BATRK 2.9B
- AGIO 2.4B
- IPO Year
- BATRK N/A
- AGIO 2013
- Fundamental
- Price
- BATRK $40.82
- AGIO $40.72
- Analyst Decision
- BATRK Strong Buy
- AGIO Strong Buy
- Analyst Count
- BATRK 3
- AGIO 5
- Target Price
- BATRK $58.00
- AGIO $57.25
- AVG Volume (30 Days)
- BATRK 280.9K
- AGIO 577.5K
- Earning Date
- BATRK 11-05-2025
- AGIO 10-30-2025
- Dividend Yield
- BATRK N/A
- AGIO N/A
- EPS Growth
- BATRK N/A
- AGIO N/A
- EPS
- BATRK N/A
- AGIO 11.13
- Revenue
- BATRK $702,443,000.00
- AGIO $40,875,000.00
- Revenue This Year
- BATRK $14.16
- AGIO $23.76
- Revenue Next Year
- BATRK $3.97
- AGIO $148.23
- P/E Ratio
- BATRK N/A
- AGIO $3.67
- Revenue Growth
- BATRK 6.51
- AGIO 30.57
- 52 Week Low
- BATRK $35.46
- AGIO $23.42
- 52 Week High
- BATRK $47.18
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- BATRK 31.41
- AGIO 63.66
- Support Level
- BATRK $40.44
- AGIO $39.32
- Resistance Level
- BATRK $41.80
- AGIO $41.42
- Average True Range (ATR)
- BATRK 0.60
- AGIO 1.34
- MACD
- BATRK 0.03
- AGIO 0.34
- Stochastic Oscillator
- BATRK 14.53
- AGIO 87.58
About BATRK Atlanta Braves Holdings Inc. Series C
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.